Clinical Evaluation of Percutaneous Implantation of the Medtronic CoreValve Aortic Valve Prosthesis (18Fr-Study)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigation concerns a prospective, multicenter, single arm safety and performance study evaluating the Medtronic CoreValve system. Approximately 120 patients presenting with symptomatic aortic native valve stenosis necessitating valve replacement which are considered poor surgical candidates, with a high surgical risk, as attested to by both the surgeon and the cardiologist are recruited in the study.
Safety and performance will be evaluated at discharge and at 30 days post-procedure. Valve performance and placement will be followed up at 3 and 6 months post-procedure. Further long-term patient follow-up visits will be performed at 12, 24, 36 and 48 months post-procedure.
| Condition | Intervention | Phase |
|---|---|---|
|
Aortic Valve Stenosis |
Device: Medtronic CoreValve System |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Clinical Evaluation of Percutaneous Implantation of the CoreValve Aortic Valve Prosthesis. Safety and Performance Study on Patients at High Risk for Surgical Valve Replacement (18Fr Safety and Efficacy Study) |
- Composite Major Adverse Events (MAE) [ Time Frame: Discharge and 30-days ] [ Designated as safety issue: Yes ]
| Enrollment: | 126 |
| Study Start Date: | May 2006 |
| Estimated Study Completion Date: | January 2013 |
| Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: CoreValve |
Device: Medtronic CoreValve System
Transcatheter Aortic Valve
Other Names:
|
Eligibility| Ages Eligible for Study: | 75 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Native aortic valve disease, defined as valve stenosis with an aortic valve area <1cm² (<0.6cm2/m2) as determined by echocardiographic measure,
- ≥ 75 years, or
- Surgical risk calculated with logistic EuroSCORE ≥ 15 %, or
One or two (but not more than 2) of the following complicating factors:
- Cirrhosis of the liver (Child class A or B),
- Pulmonary insufficiency : Forced expiratory volume in one second (FEV1) < 1 liter,
- Previous cardiac surgery (Coronary artery bypass grafting (CABG), valvular surgery),
- Pulmonary hypertension > 60 mmHg and high risk of cardiac surgery other than valve replacement,
- Porcelain aorta
- Recurrent pulmonary embolus,
- Right ventricular insufficiency,
- Thoracic burning sequelae contraindicating open chest surgery,
- History of mediastinum radiotherapy,
- Severe connective tissue disease resulting in a contraindication to surgery,
- Cachexia (BMI ≤ 18 kg/m²),
- Aortic valve annulus diameter is ≥ 20 mm and ≤ 27 mm as determined by echocardiographic measure,
- Ascending aorta diameter £ 45 mm at the sino-tubular junction, and
- Signed Informed Consent.
Exclusion Criteria:
- Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, Nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated,
- Any sepsis, including active endocarditis,
- Recent myocardial infarction (< 30 days),
- Percutaneous coronary or vascular intervention within 15 days prior to the study procedure, or scheduled during or within 30 days after the study procedure,
- Any left ventricular or atrial thrombus diagnosed by echocardiography,
- Uncontrolled atrial fibrillation (heart rate greater than 100 bpm),
- Mitral or tricuspid valvular insufficiency ( > grade II),
- Previous aortic valve replacement (mechanical valve OR stented bioprosthetic valve),
- Any condition considered as contraindication for extracorporeal assistance,
- Evolutive or recent CVA (cerebro vascular accident),
Poly arterial patients with either:
- Femoral, iliac or aortic vascular condition (e.g. stenosis, tortuosity), that make insertion and endovascular access to the aortic valve impossible, or
- Symptomatic carotid or vertebral arteries narrowing (> 70%) disease, or
- Abdominal or thoracic aortic aneurysm,
- Bleeding diathesis or coagulopathy, or patient who will refuse blood transfusion,
- Evolutive disease with life expectancy less than one year,
- Creatinine clearance < 20 ml/min,
- Pregnancy, and
- Enrolled in another investigational study.
Contacts and Locations| Canada | |
| University of Alberta Hospital | |
| Edmonton, Canada | |
| Institut de Cardiologie de Montreal | |
| Montreal, Canada | |
| University of Ottawa Heart Institute | |
| Ottawa, Canada | |
| Germany | |
| Herzzentrum Leipzig GmbH | |
| Leipzig, Germany | |
| HELIOS Heart Center Siegburg | |
| Siegburg, Germany | |
| Netherlands | |
| Amphia Hospital | |
| Breda, Netherlands | |
| Erasmus MC | |
| Rotterdam, Netherlands | |
| United Kingdom | |
| Glenfield Hospital | |
| Leicester, United Kingdom | |
| Royal Brompton & Harefield NHS Trust | |
| London, United Kingdom | |
| Principal Investigator: | E. Grube, Prof. Dr. | Helios Heart Center Siegburg, Germany |
| Principal Investigator: | G. Schuler, Prof. Dr. | Herzzentrum Universitat Leipzig, Germany |
| Principal Investigator: | R. Bonan, Dr. | Institut de Cardiologie de Montreal, Canada |
| Principal Investigator: | J. Kovac, Dr. | Glenfield Hospital Leicester, UK |
| Principal Investigator: | P. Serruys, Prof. Dr. | Erasmus MC Rotterdam, Netherlands |
| Principal Investigator: | M. Labinaz, Dr. | University of Ottawa Heart Institute, Canada |
| Principal Investigator: | P den Heijer, Dr. | Amphia Hospital Breda, Netherlands |
| Principal Investigator: | M Mullen, Dr. | Royal Brompton & Harefield NHS Trust London, UK |
| Principal Investigator: | W. Tymchak, Dr. | University of Alberta Hospital, Canada |
More Information
Additional Information:
No publications provided
| Responsible Party: | Medtronic Bakken Research Center |
| ClinicalTrials.gov Identifier: | NCT01051518 History of Changes |
| Other Study ID Numbers: | COR-2006-02 |
| Study First Received: | January 15, 2010 |
| Last Updated: | January 27, 2012 |
| Health Authority: | Netherlands: Ministry of Health, Welfare and Sport Germany: Ministry of Health United Kingdom: Department of Health Canada: Health Canada |
Additional relevant MeSH terms:
|
Aortic Valve Stenosis Heart Valve Diseases Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction |
ClinicalTrials.gov processed this record on May 19, 2013